Category:

Eco/Invest/Demography

Govt asks Serum, Bharat Biotech to lower price of Covid vaccines: Report

The Hyderabad-based Bharat Biotech has fixed the price of its COVID-19 vaccine, Covaxin, at Rs 600 per dose for state governments and at Rs 1,200 per dose for private hospitals.

The Pune-based Serum Institute of India (SII), the world’s largest vaccine maker in terms of volume, has announced a price of Rs 400 per dose for its COVID-19 vaccine, ‘Covishield’, for state governments and Rs 600 per dose for private hospitals.

Both vaccines are available to the central government at a rate of Rs 150 per dose.

read more

Europe embraces digital health pass,to face security, fraud, political challenges

The EU Commission plans to award a contract this month for a central system for verifying the digital passes, which will use QR codes that can be scanned into a smartphone app. It will also provide a template to help member countries develop their own apps – though some have already readied their own versions.

There is still no consensus on whether antibody tests provide sufficient proof that a person who has recovered from COVID-19 is immune, sources involved in the efforts say.
Member states also worry about the security of personal information, though the Commission has promised the online certificates will contain minimal data: name, date of birth, the specific health information, its date of issue and a unique identifier code.

read more

World’s fastest recovery outlook at risk as coronavirus sweeps India

That uncertainty doesn’t look to be going away in a hurry, with India adding more than 300,000 cases daily for at least three consecutive days last week, pushing the total infections to more than 16.5 million. While the outbreak has overwhelmed the nation’s hospitals and crematoriums, it’s also hit consumer confidence in an economy that was only beginning to recover from an unprecedented recession last year.

read more

Covid surge likely due to lack of antibodies in seropositive people: CSIR

According to the paper, the aggregate sero-positivity of 10.14 per cent in its multi-centre study suggests India had a large pool of recovered immune subjects by September 2020, especially amongst its high contact workers and people using public transport, leading to a decline in new infections.

“However, the duration of such immunity may not be sufficient to prevent future outbreaks, even in highly affected regions, the paper said.

read more